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1. Introduction
Hepatitis is an inflammation of the liver. There are at least five different viruses causing
hepatitis. Each of the five major hepatitis viruses, hepatitis A virus (HAV), hepatitis B virus
(HBV), hepatitis C virus (HCV), delta hepatitis virus (HDV) and hepatitis E virus (HEV) belong
to a separate family. Currently, all these viral hepatitis (A-E) have been classified into different
genotypes and subgenotypes. Several factors, including viral genotypes have been reported
to be associated with disease progression and treatment response. Consequently, documen‐
tation of genotype recently have been proved to be a valuable tool not only for epidemiological
reasons but also for clinical implications and treatment.
2. Hepatitis A virus
HAV is a member of the Hepatovirus genus of Picornaviridae family. HAV is a non-enveloped
(naked), linear, single stranded RNA virus of an icosahedral symmetry measuring 27-32 nm
in diameter [1]. HAV infection is hyper-endemic in vast areas of the world, with approximately
1.5 million clinical cases per year [2]. The worldwide distribution is uneven and is based on
determinants such as socioeconomic conditions and geographic factors [3-5]. In developing
countries, the incidence of disease in adults is relatively low because of exposure to the virus
in childhood. Most adults in these areas show prevalence of antibodies against hepatitis A. In
developed world endemicity is usually very low and clinical cases occur almost exclusively in
adults [6,7]. The variable age distribution among hepatitis A patients in developing and
developed countries is a consequence of differing standards of hygiene and sanitation. In many
developing countries, improved hygiene standards and socio-economic conditions have led
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to a reduction in exposure to HAV in childhood and hence large non-immune adult population
in the community. This leads to a shift or transition from asymptomatic childhood infections
to an increased incidence of symptomatic or clinical disease in adults [8]. The persistence of
circulating HAV may lead to hepatitis A outbreaks in susceptible non-immune adult popula‐
tion [8,9].
2.1. Disease severity
HAV causes an acute self-limited illness. The vast majority of hepatitis A patients make a full
recovery and fatality rate is low. The estimated mortality rate is 0.1% for children less than 15
years old, 0.3% for adults ages 15 to 39, and 2.1% for adults ages 40 and old [10,11]. HAV does
not lead to chronic hepatitis or a carrier state and only rarely leads to fulminant hepatic failure
(FHF) [12]. FHF occurs during the first 4-6 weeks of illness which is characterized by sudden
onset of high fever, marked abdominal pain, vomiting and jaundice followed by development
of hepatic encephalopathy associated with deep coma and seizures [13,14]. Mortality is highly
correlated with increasing age, survival being rare over the age 45 years [15]. The acute HAV
super infection with chronic liver disease is also associated with severity and high mortality
[16,17].
2.2. Genomic organization
Like all picornaviral genomes, HAV is divided into three parts: (i) 5’ non-coding region (NCR)
that comprises approximately 10% of the genome (ii) single open reading frame (ORF) of 2227
amino acids, that encode all the viral proteins, with regions designated as P1 for capsid
proteins, P2 and P3 for non-structural proteins and (iii) short 3’ non-coding region (Fig. 1).
Figure 1. Genomic organization of hepatitis A virus: HAV genome is divided into a 5’ non-coding region (5’ NCR), a
giant open reading frame, and a 3' non-coding region (3’ NCR). The coding region is subdivided into regions P1, P2
and P3. (Adapted from: Ref. 20)
HAV RNA genomes lack the cap assembly found at the 5’ end of mRNA species that normally
guides the ribosomal complex to the translation start site [18]. Instead, an internal ribosome
entry site (IRES) formed by the 5’NCR functions to initiate translations in HAV including other
picornaviruses [19, 20]. However, unlike other picornavirus IRESes, the HAV IRES requires
an intact eukaryotic initiation factor 4G for its optimal activity [20]. Several other host proteins
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are found to be associated with synthetic RNAs representing segments of the 5’ NCR [21]. The
viral capsid protein (P1) is further divided into VP4, VP2, VP3 and VP1 regions. The non-
structural P2 and P3 polyproteins are divided into 2A, 2B, 2C and 3A, 3B, 3C, 3D respectively
(Fig. 1). HAV polyprotein is processed into precursor intermediates and mature proteins by
the proteolytic activities of encoded viral proteins. HAV 2A, 2B, 2C protein encodes 45, 251
and 335 amino acids respectively. The 2A and 3C are identified as processing enzyme in
hepatitis A virus. The translated 2A regions function as intermediary, partially located on the
surface (VP1) and some are assembled inside the virion [20]. Both 2B and 2C proteins play an
important role in the replication of the viral RNA. P3 polyproteins encodes 3A, 3B, 3C and 3D
proteins with 74, 23, 219 and 489 amino acids respectively. 3C protein acts as sole protease for
HAV protein processing, while 3D is the RNA dependent RNA polymerase [22].
2.3. HAV genotypes and geographic distribution
Genetic heterogeneity of hepatitis A has been revealed by sequencing different genome
regions, including VP3 carboxyl terminus, the VP1 amino terminus and the VP1/2A junction
[23-25] (Fig. 2). The VP3 C-terminal region is relatively conserved, the VP1 amino acid terminus
presents an intermediate variability, while VP1/2A junction is more variable and is used to
distinguish one strain from another [25]. The genetic variability observed within the putative
VP1/2A junction (168 nucleotides) initially defined seven (I-VII) genotypes [26-29]. However,
recently new classification of HAV has been done based on the complete sequences of the 900
nucleotides of VP1 region [30] (Fig. 2).
Figure 2. The genomic organization of VP3 C-terminal, the VP1 amino acid terminal and VP1/2A junction region of
hepatitis A virus. The complete sequence of the 900 nucleotides of the VP1 gene has been used for new classification
of HAV. (Adapted from: Ref. 30)
The phylogenetic analyses of VP1 sequences identified six genotypes (I-VI) that differ among
themselves 15-25%. Three isolated from humans (I-III) and three from a simian origin (IV-VI).
The genotypes I, II and III were further subdivided into sub-genotypes A and B, which differ
in approximately 7.5% of base positions. The worldwide genotype distribution showed
genotype I and III comprise the vast majority of human strains within the studied population
(Fig. 3). Sub-genotype IA comprises the majority of the human strains studied and constitutes
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major virus population in North and South America, China, Japan, Russia and Thailand. The
sub-genotype IB contains strains from Jordan, North Africa, Australia, Europe, Japan and
South America. Most of the remaining human HAV strains segregate into genotype III that is
further divided into two sub-genotypes, IIIA, and IIIB [23,27,29]. The sub-genotype IIIA have
been subsequently identified in specimens collected from humans with hepatitis A in India,
Sri Lanka, Nepal, Malaysia, Sweden and the U.S.A [26,31].The IIIB sub-genotype is responsible
for cases of HAV infection in Japan and Denmark.
Figure 3. Worldwide distribution of hepatitis A virus genotype(s) according to the VP3 carboxyl terminus, the VP1
amino terminus and the VP1/P2A junction. (Adapted from: Ref. 4, 23, 26, 27, 29, 30 & 31)
2.4. Effect of HAV genotype on disease severity
Although, HAV causes an acute self-limited illness but rarely, it also involved in severe course
such as fulminant hepatitis, relapsing hepatitis, prolonged and cholestatic hepatitis. The
question arises, if genetic heterogeneity/ genotypes play any role in self-limiting or severe
course of the disease. There are contradictory reports regarding the role of HAV genotype in
disease severity. Fujiwara et al., [32], reported an association between the severity of hepatitis
A and nucleotide variations in the central portion of the 5' NCR of Japanese HAV RNA. Similar
study from South Korea reported no association between 5’NCR sequence variations and
disease severity [33]. Several other studies also reported no association between genotype or
nucleotide changes with disease severity [34-37]. Recently, a comparative analysis of disease
severity between genotype 1A and IIIA revealed that the patients with genotype IIIA were
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older and had high alanine aminotransferase (ALT) levels, prolonged prothrombin times and
lower serum albumin level [38]. Another study indicated that co-infection of 2 sub-genotypes
(1a and 1b) in a patient with acute hepatitis accounted for the prolonged and severe course of
illness [39]. Therefore, additional studies are needed to define the precise role of viral geno‐
types in the severity of hepatitis A.
2.5. HAV genotype and antiviral treatment response
Since most of the cases are self-limiting, acute HAV does not require antiviral therapy in
immunocompetent patients related to any genotype. The immunosuppressed patients should
be recommended ribavirin, so that these patients should not progressed to cirrhosis. Liver
transplantation is the only treatment option for patients with fulminant hepatic failure due to
HAV. Since hepatitis A exists as a single serotype and human is the only host, it is possible to
eradicate by selective vaccination against individuals who are susceptible and sero-negative
for HAV-IgM.
3. Hepatitis B virus
HBV is a member of the Hepadnaviridae family and is known to be one of the smallest human
DNA virus [40,41]. HBV infection is very common worldwide with more than 350 million (5%)
of the world's population is chronic carriers [42-44]. Most acute infections with hepatitis B virus
are self-limited with clearance of virus and development of immunity [45,46]. However, an
estimated 5% to 10% of adults and 85% to 95% of children develop chronic hepatitis B virus
infection [47].The prevalence of HBV infection varies throughout the world [44,48]. The
prevalence of HBV infection in Asia and Africa is high (8%), with perinatal and early childhood
transmission resulting in a high rate of chronicity [44,46,48]. The Mediterranean and Eastern
Europe have an intermediate (3-5%) endemicity and maintained mainly through sexual,
household, nosocomial and perinatal transmission [44,46,48]. The prevalence of chronic
infection in some areas of Europe, North America and Australia is less than 1% and disease is
mostly transmitted via sexual contact or through intravenous drug use [46].
3.1. Disease severity
Chronic hepatitis B (CHB) is responsible for 1 million deaths per year globally [49]. It is a major
cause of cirrhosis of the liver and hepatocellular carcinoma (HCC) worldwide [50,51].The
integrity of the host immunological system, viral replication and probably the genetic heter‐
ogeneity (genotypes and mutations) of the (HBV) play an important role in the determination
of the natural history [52,53]. However, the high morbidity and mortality associated with
chronic HBV results in a substantial medical and economic burden on healthcare systems,
marking HBV as an international health problem [52,53].




HBV is an enveloped virus (42-47 nm in diameter) with an inner icosahedral nucleocapsid
containing DNA genome [54]. The viral genome is approximately about 3.2 kb long, partially
double-stranded relaxed circular (rc-dsDNA) structure and covalently bond to the viral
encoded DNA polymerase [50,55-57]. The HBV genome has a highly compact coding structure
consisting of four overlapping reading frames (ORF) designated as P (polymerase), S (surface/
envelope), Pre-C/C (core) and X (HBx protein) (Fig. 4) [55,56,58].The polymerase ORF is the
largest and it overlaps the X, the core and the pre-S/S. The pre-S/S ORF has 3 initiation codons
encoding the small hepatitis B surface protein (SHBs), middle hepatitis B surface protein (preS2
+ S) and large hepatitis B surface protein(pre-S1 + pre-S2 + S) proteins. C ORF encodes the core
protein (HBcAg) and pre-core or e’ antigen (HBeAg) and it contains an N-terminal extension
of 29 amino acids [55,56,58,59].
Figure 4. The schematic representation of HBV genome. The circular HBV genome is presented as a linear form. The
coding regions for e/core, surface, polymerase and X proteins are designated as Pc/C, S, P and X respectively. (Adapt‐
ed from: Ref. 59, 55 & 58)
3.3. HBV genotypes and geographic distribution
HBV can be classified into 10 genotypes A to J, based on the comparison of complete HBV
genomes [60-64]. These genotypes are based on a divergence of 8% or more in the complete
nucleotide sequence of the entire viral genome [61-64]. There are numerous subgenotypes
(currently approximately 24) has been identified based on genetic diversity of HBV [65,66].
These subgenotypes were differentiated by a sequence divergence by at least 4% [65,66]. Since
genotypic variation of HBV is reflected in a partial sequence of HBV, therefore genotyping of
HBV is possible without determining the entire genomic sequence [60,67,68]. As shown in Fig.
5, the S gene is more conserved than the pre-S region, therefore the analysis of the S gene is
much more suitable for genotyping. Recently, a fragment of 1306 bp partially comprising
HBsAg and polymerase coding regions(S/POL) has also been used for genotyping (Fig. 5) [69].
Several methods have been employed to genotype hepatitis B virus; (a) Direct sequencing [70]
(b) Restriction fragment length polymorphism (RFLP) [71] (c) Line Probe Assay (LiPA) [72] (d)
Genotype specific PCR [73].
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Figure 5. Common genotyping region of HBV genome. The most suitable region for genotyping is S and S/Pol indicat‐
ed by dotted line (…). (Adapted from: Ref. 60, 67, 68 & 69)
The distribution of HBV genotypes varies across different geographical regions (Fig. 6). HBV
Genotype A is most commonly found in the Americas, Africa, India and Western Europe [74,
75]. Genotype B is most common in Asia including Japan, Taiwan, Indonesia, China and
Vietnam [76-79]. Genotype C is predominant in East Asia and countries of the Pacific Rim [68],
while genotype D most commonly found in the Mediterranean, India, Middle East [75,80-82].
HBV genotype E is mainly identified in sub-Saharan Africa, genotype F in South and Central
America as well as Alaska, and genotype G in Central and North America as well as Europe
[83-85]. The most recent HBV genotype identified, genotype H, has been found in the United
States, Mexico and Central America [86,87]. The genotype F is the most distantly related
genetically of the other HBV genotypes (12.8-15.5%) [88]. Recently, genotype I, a novel inter-
genotypic recombination among genotypes A, C and G was isolated in Vietnam and Laos [89].
The newest HBV genotype J, was identified in the Ryukyu island in Japan, and this genotype
has a close relationship with gibbon, orangutan and human genotype C [90]. The epidemiology
of HBV infection is still shifting and the apparent variations in geographical distribution of
genotypes is effect of migration from countries with a high prevalence of HBV infection to
countries with a lower prevalence.
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3.4. Effect of HBV genotypes on disease severity
There are conflicting report about the role of HBV genotypes and severity of the disease. Recent
study from Japan demonstrated that genotype B is associated with slower progression to
cirrhosis of the liver compared to genotype C [91]. Another study suggested that acute infection
with HBV genotype A increases the risk of progression to chronic infection [79,92]. In China,
the patients contracted with HBV subtype C2 develops chronic infection more often than those
infected with subtype B2 [78,93]. There are conflicting reports from India; one study found that
patients infected with genotype D strains had severe chronic liver disease, while another study
could not find genotype D strains to be involved in severity [75,94]. Study from East Asia
indicated, genotype C as a predominant genotype in subjects with advanced chronic hepatitis
(CH), liver cirrhosis (LC) and hepatocellular carcinoma (HCC) [95]. Taiwanese study demon‐
strated association of genotype C as a risk factor for HCC than genotype B [93,96]. A study
from Hong-Kong found that patients infected with genotype B had a higher rate of hepatic
decompensation compared to genotype C patients [97]. The HBV patients contracted fulmi‐
nant hepatitis are more often associated with genotype B [98]. The characteristics of other
genotypes (E-J) with disease severity has not been well documented.
Figure 6. Worldwide geographic distribution of HBV genotypes. (Adapted from: Ref. 68, 74, 75, 77, 79, 81, 82, 83, 84,
86, 87, 88, 89 & 90)
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3.4.1. Do genotypes influence seroconversion and seroclearance?
The seroconversion of e’ antigen (HBeAg) and seroclearance of surface antigen (HBsAg) are
important steps in the natural history of chronic HBV infection [99-102]. Early HBeAg
seroconversion typically confers a favorable outcome, while late or absent HBeAg serocon‐
version after multiple hepatitis flares may accelerate the progression of chronic hepatitis to
cirrhosis and hence a poor clinical outcome [99-102]. How these events are influenced by HBV
genotypes are subject to a proper understanding and research? Taiwanese study demonstrated
that genotype C infection was associated with lower rates of spontaneous HBeAg serocon‐
version than genotype B [101]. In case of HBsAg seroclearance, the HBV genotypes A and B
patients had high frequency compared to genotypes C and D patients [83, 103].
3.4.2. Do genotypes influence frequency of viral mutations?
Several studies revealed that genotypes do influence the frequency of mutations in HBV
genetic make-up. The HBV genotype C infections conferred a higher frequency of basal core
promoter (BCP) A1762T/G1764A mutation than genotype B [104,105]. Similarly, patients with
genotype D infection had a higher prevalence of BCP A1762T/G1764A mutation than those
with genotype A infection [106]. The nucleotide(s) deletion within pre-S region is reported to
be associated with genotypic variations. The pre-S deletion was higher in genotype C than
genotype B patients [107]. In addition, the presence of pre-S deletion was an independent risk
factor associated with disease progression as well as HCC development [108-110].
3.5. HBV Genotype and antiviral treatment response
According to different investigators, the nucleotide sequence diversity among different
isolates of the virus may play a significant role in response to therapy. The impact of HBV
genotype on therapeutic response has been reported in several studies [111,112]. HBV
genotype plays a vital role in sustained response (i.e. normalization of serum ALT level and
HBeAg seroconversion post treatment) rate. The HBeAg positive patients treated with
standard IFN-a, the sustained response rate is significantly better in genotype A and B patients
than for genotype C and D [113-116]. Contrary to genotype A-D, patients infected with
genotype E–J are rarer and their responses to IFN-based therapy remain largely unknown. In
patients treated with nucleos (t) ide analogues, sustained response rate was contradictory in
relation to genotype [117,118].
4. Hepatitis C virus
HCV is a small size (55-65 nm), enveloped virus, belong to a member of the family Flaviviri‐
dae [119,120]. It is mainly transmitted by exposure to contaminated blood or blood products
[121,122]. This virus is target specific and replicates in the hepatocytes (liver cells). The initial
phase of hepatitis C is called the acute infection [123]. The symptoms of acute HCV infection
includes fatigue, jaundice, appetite loss, abdominal pain, nausea and vomiting, joint pain, dark
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urine and clay-colored stool [124]. Sixty to seventy percent of people in the acute stage have
no symptoms and hence most of HCV cases often goes undiagnosed [123,125]. On the other
hand, patients who develop symptoms, the average time period between exposure and
symptom onset is 4-12 weeks. Fifteen to twenty percent of acute cases spontaneously clear this
virus within 2-12 weeks. However, up to 80% of people initially infected with HCV do not
clear the virus from their bodies, and continue to have liver disease with 55% develops chronic
liver disease [126,127]. Chronic hepatitis C is often silent, most of the times discovered only by
routine serological, biochemical and radiological testing [128].
4.1. Disease severity
HCV is a major cause of liver associated disease all over the world with an estimated 3% of
the world’s populations are chronically infected [129,130]. In some endemic areas, such as the
Middle East, North-East Asia and South Africa, the prevalence of HCV infection is as high as
20-30% [122]. Chronic infection often progresses to liver fibrosis, cirrhosis and hepatocellular
carcinoma (HCC) in a substantial number of patients [126-128]. The rate of disease progression
is variable and several factors have been identified as important in predicting the outcome of
progression such as age at infection, gender, genotype/subtype, viral load, and mode of
infection.
4.2. Genome organization
HCV viral genome is positive sense RNA with approximately 9.4 kb in length containing a
poly (A) tail at the 3’end (Fig. 7). The sequence contained a 5’untranslated region (5’ÚTR) of
341 bases and 3’UTR of about 27 bases [120,131, 132]. The HCV genome has a single open
reading frame coding for a polyprotein of 3010 amino acids. The poly-protein is cleaved after
translation into structural and non-structural proteins necessary for viral replication and virion
formation. The structural proteins situated towards the N-terminus of the genome and non-
structural genes located near C-terminal. The 5’UTR is most conserved region of HCV and is
pivotal for the initiation of translation and ribosomal binding [133-135]. The structural genes
code for the capsid (core) protein (C) and envelope glycoproteins (E1, E2) [133,134]. The first
27 amino acids of the E2 gene constitute the hyper-variable region 1 (HVR1) of the genome
and seems to be involved in virus evasion of the immune system and disease progression [136].
The non-structural genes code for a protease (NS2, NS3) and its cofactor (NS4A), a helicase
(NS3), a protein of unknown function (NS4B), a phosphoprotein (NS5A), and an RNA-
dependent RNA polymerase (NS5B) [137].
The virus replicates in the cytoplasm using an RNA-dependent RNA polymerase that lacks
general proofreading ability [138]. This error-prone RNA polymerase is responsible for the
genetic variability exhibited by HCV isolates and high spontaneous nucleotide substitution
rate with a frequency of 10–2 to 10–3 substitutions per nucleotide site per year [139]. HCV cir‐
culates as a heterogeneous population or quasispecies which differ by 1-5%in nucleotide se‐
quence diversity [140]. Quasispecies permits rapid adaptability of the virus in the event of
environmental changes and a clever strategy utilized by the virus to escape selective forces
such as nucleotide antiviral agents or the immune system [139,140].
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Figure 7. Genomic organization of HCV: The HCV genome contains a single open reading frame (ORF). The genes for
structural proteins (C, E1, E2, P7) are situated towards the N-terminus of the ORF. Genes coding for proteins necessary
for viral replication are found towards the C-terminus of the ORF. (Adapted from: Ref. 120, 131 & 133)
4.3. HCV genotypes and geographic distribution
The HCV genotype has been determined primarily based on analysis of partial genome
sequences. Investigators have typically used sequence analysis of NS5B, core, E1, and 5'UTRs
for HCV genotyping (Fig. 8). The most widely accepted classification system of HCV geno‐
typing is that of Simmonds et al. 1993 [137]. This system is based on the sequence variability
of the 222 base pairs of the NS5B region and it divides HCV isolates into six phylogenetically
distinct groups, and more than 80 subtypes. However, following the description of the new
genotypes 7-11, Robertson et al., 1998, measured that it was more accurate for the genotypes
7, 8, 9 and 11 to be assigned as subtypes of genotype 6 and the genotype 10 to be a subtype of
the genotype 3 [141]. Several methods have been employed to genotype hepatitis C virus; (a)
Direct sequencing [140] (b) Restriction fragment length polymorphism (RFLP) [142] (c) Line
Probe Assay (LiPA) [143] (d) Genotype specific PCR [144].
Figure 8. Genotyping region of HCV: The most suitable region for genotyping are 5’ UTR, Core (C), E1 and NS5B indi‐
cated by dotted (…) line. (Adapted from: Ref. 138, 140, 141, 146 & 147)
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At least 6 major genotypes of HCV, each comprising multiple subtypes have been identified
worldwide [138,145-147]. Each genotype is separated by sequence divergence in the entire
genome exceeding 30%. Substantial regional differences appear to exist in the distribution of
HCV genotypes (Fig. 9). Although HCV genotypes 1, 2, and 3 appear to have a worldwide
distribution, their relative prevalence varies from one geographic area to another [145]. HCV
subtypes 1a and 1b are the most common genotypes in the United States [145]. These subtypes
also are predominant in Europe [148]. In Japan, subtype 1b is responsible for up to 73% of cases
of HCV infection [149]. Although HCV subtypes 2a and 2b are relatively common in North
America, Europe, and Japan, subtype 2c commonly found in northern Italy [146]. HCV
genotype 3a is particularly prevalent in intravenous drug abusers in Europe and the United
States [150]. HCV genotype 4 appears to be prevalent in North Africa and the Middle East [151,
152], type 5 mainly in South Africa and type 6 principally in Hong Kong and Southeast Asia
[137,153]. Mixed genotype infections from a major and a minor HCV population accounts for
4-17% of HCV patients [154].
4.4. Effect of genotype on disease severity
In recent years, substantial evidence has emerged indicating the role of HCV genotypes in
disease severity and sensitivity to the antiviral therapy [140,146]. Importantly, patients infected
with any of the 6 genotype can develop advanced liver disease, including cirrhosis and HCC.
However, some genotypes appear to be more severe compared to the other. For example,
Chronic HCV patients infected with genotype 1b is reported to be associated with a more
severe liver disease and a more aggressive course compared to genotype 2 (146,155-157]. HCV
genotype 1b has also been reported to be associated with the development of advanced liver
disease including cirrhosis and hepatocellular carcinoma (HCC) compared to other genotypes
(157,158]. However, other investigators failed to arrive at the same conclusions for genotype
1b and therefore further studies are required to elucidate any role of HCV genotype in disease
progression or severity [159-162]. A study from India, indicate that most of the chronic hepatitis
patients related to genotype 3 is associated with significant steatosis (accumulation of fat
within hepatocytes) and fibrosis [163]. Another study report steatosis regardless of genotypes,
but resolution of viral infection from genotype 3a patients is associated with disappearance of
steatosis and hence genotype 3a and steatosis are interlinked [164]. According to latest statistics
15% of Egyptians are infected with HCV and most of these patients have genotype 4 [165,166].
Genotype 4 has also been associated with a severe disease and increased development of HCC
[165]. HCV Genotype 5 is associated with higher mean age compared to other HCV genotype
infection [167]. Report from Hong Kong suggested prominence of genotype 6 in patients with
thalassemia major and intravenous drug abusers [168].
4.5. HCV genotype and antiviral treatment response
The main objective of therapy administered to patients with chronic hepatitis C is to achieve
a Sustained Virological Response (SVR). SVR is characterized by the clearance of serum HCV
RNA at the end of therapy and maintained throughout the 6-month follow up period after
completion of treatment [169]. The current treatment for HCV infection is two daily doses of
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ribavirin (non-specific anti-viral agent) combined with a weekly injection of interferon-α
(standard or pegylated) [170]. The recommended treatment length depends on the virus
genotype. Patients with genotypes 2 and 3 are almost three times more likely than patients
with genotype 1 to respond to the combination of alpha interferon and ribavirin therapy [129,
164, 171, 172]. Notably, patients with genotype 2 and 3, a 24 week course of combination
treatment is adequate, whereas a 48 week course is recommended for genotype 1 [172].
Although, the response of combination therapy against genotype 2 and 3 is better, still there
are moderately high percentage of non-responders. The re-treatment response involving
combination therapy in non-responders are still better in genotype 2 and 3 (50-60% SVR)
compare to genotype 1 (14%) [173]. Genotype 4 presents advance liver disease in patients, and
response to Interferon-Ribavirin combination therapy is moderate with ~60% SVR after 48
weeks treatment [174]. Similarly, among genotype 5 patients, the response rate achieved is
more than 60% SVR, when treated with Interferon-Ribavirin combination therapy for 48 weeks
[175]. HCV genotype 6 responds better to Interferon-Ribavirin combination therapy compare
to genotype 1 with treatment duration of 48 weeks [176].
5. Hepatitis D virus
HDV was first discovered in 1977 among a group of patients infected with hepatitis B virus
[177]. HDV depends on the HBV to provide hepatitis B surface antigen (HBsAg) for virion
Figure 9. Worldwide geographic distribution of HCV genotypes. (Adapted from: Ref. 138,146,147 & 152)
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assembly and propagation [178]. There are approximately 350 million chronic HBV carriers of
the virus, according to the available data 5% (15 million) of these HBV carriers are infected
with HDV [179,180]. HDV is highly endemic in Mediterranean countries, Middle East, Central
Africa, and northern parts of South America [181]. In contrast, in industrialized countries, its
prevalence is low and its transmission is often associated with intravenous drug use [182].
HDV is transmitted through blood and body fluids, quite similar to that of HBV [183]. Hepatitis
D symptoms are identical to other viral hepatitis diseases and include jaundice, fever, malaise,
dark urine and nausea [183].
5.1. Disease severity
HDV propagates in human hepatocytes as its natural host but only in presence of hepatitis B
virus, causing severe acute, fulminant or chronic hepatitis leading to liver cirrhosis [179, 184,
185]. HDV infection can occur either as a co-infection with HBV or as a superinfection in
patients with chronic HBV infection [179]. The individuals with HBV-HDV co-infection
resulted in more severe acute disease and a higher risk of fulminant hepatitis than HBV alone
(1983). Only 2% of co-infected patients resulted in chronic infection [186]. Super infection with
HDV in HBV chronic carriers leads to higher incidence of cirrhosis and hepatocellular
carcinoma [187]. A factor that may influence the course of disease is the genetic heterogeneity
of HDV prevalent in different geographical areas [188].
5.2. Genome organization
The HDV virion is a spherical particle of about 36-nm in diameter, which contains an envelope
(HBsAg) and a nucleocapsid containing an RNA genome in complex with HDAg [189-191].
HDV particles consist of a negative sense, circular, single-strand RNA genome, approximately
1.7 kb in length. HDV anti-genome contains a unique open reading frame that encodes the
small (sHD) and large hepatitis delta (LHD) proteins. The sHD and LHD correspond respec‐
tively to the small-p24 and the large-p27 hepatitis delta proteins [192]. The LHD amino acid
sequence is identical to sHD except with the extension of 19 to 20 amino acids at carboxy-
terminal end [192, 193]. sHD is required for viral replication and might promote RNA
polymerase II elongation of nascent HDV RNA, while LHD inhibits HDV RNA replication
and is required for HDV RNA packaging with the HBV envelope protein [194].
5.3. HDV genotypes and geographic distribution
To date researchers have identified 8 major clades or genotypes of hepatitis delta virus
based on phylogenetic analysis and are labeled as HDV-1 to HDV-8 [195]. These genotypes
are mostly defined based on the analysis of 357 nucleotide semi-conserved region of HDV
genome [187,196,197] (Fig. 10).The sequence differences among these genotypes are signifi‐
cant; there is a divergence of 40% in nucleotide sequence and 35% in amino acid sequence of
HDAg. Distribution of genotype 1 is ubiquitous which includes European, North American,
African, and some Asian isolates [187,196-199]. Genotype 2 has been found in Japan, Taiwan
and Yakoutia (Russia) [200]. Genotype 3 has been found exclusively in Central and South
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America [187]. Genotype 4 was mostly prevalent in Japan and Taiwan [200,201]. Genotype
5-8 has been exclusively found in Africa [195] (Fig. 11).
Figure 10. Genotyping region of HDV: The most widely used region for genotyping is spanning 908-1265 nucleotide,
which encodes the second half of HDAg protein indicated by dotted line (…). (Adapted from: Ref. 190)
Figure 11. Worldwide geographic distribution of HDV. (Adapted from: Ref. 181 & 195)
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5.4. Effect of genotype on disease severity
The genetic variant of hepatitis D virus along with geographical location and transmission
route have been identified as important determinants of disease severity [202,203]. At one
geographic location genotype 1 has been associated with fulminant hepatitis and hepatocel‐
lular carcinoma [196], while in other locality the same genotype have a mild clinical course
[197,199]. The diversity observed among genotype HDV-2 has been associated with a less
aggressive course, lower ALT values and HDV RNA levels than genotype HDV-1[196,204].
Genotype HDV-3 is endemic in northern South America and is associated with a severe clinical
course [184]. Genotype HDV-4 (previously labeled HDV-IIb) also showed variable severity
depending upon the geographic location [200,201,205]. Genotype HDV (5-8), mostly observed
in African patients, most patients suffered from active chronic hepatitis or cirrhosis [181,195].
5.5. HDV Genotype and antiviral treatment response
There is no specific treatment for HDV infection. Treatment of chronic delta hepatitis is not
very effective using long-term administration of high doses of interferon-alpha [206]. It is not
known whether some HDV genotypes might be more susceptible to therapy than others.
Although, there is no specific vaccine for HDV but vaccination of persons at high risk of
acquiring HBV will prevent the acquisition of HDV infection.
6. Hepatitis E virus
HEV infection is a significant public health problem in many parts of the world, especially in
developing countries [207-209]. It is estimated that about 2 billion people live in areas endemic
for HEV [207,208]. HEV is transmitted via the fecal-oral route and target population includes
young to middle aged adults [210]. Patients infected with HEV present with nausea, vomiting,
anorexia, jaundice, abdominal pain, fever, and hepatomegaly [211]. It causes large outbreaks
of acute hepatitis but usually resolves without any therapy [212-214]. The infected individual
therefore develops antibodies that protect against future infection.
6.1. Disease severity
The clinical presentation of this disease ranges from subclinical to fulminant hepatic failure
[215,216]. HEV is a major cause of fulminant hepatitis in endemic areas such as India and
Bangladesh [216]. Hepatitis E has a mortality rate of 1-4% in the general population [211].
Increased morbidity and mortality is observed in chronic liver disease patients superinfected
with HEV [215]. The endemic area is frequently associated with increased incidence and
severity in pregnant women with around 15-20% mortality rate [217]. More than one-fourth
of affected women have obstetric complications, such as premature rupture of membranes and
intrauterine growth restriction [218,219]. It is unknown why HEV causes severe disease in
pregnant women.
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6.2. Genome organization
HEV is a spherical, non-enveloped virus of about 27–34 nm, classified currently as the sole
member of the genus Hepevirus in the family Hepeviridae [210,220,221]. Its genome is a single
stranded, positive-sense 5’capped RNA of approximately 7.2 kb in length [222,223]. It contains
three overlapping open reading frames (ORF1, ORF2 and ORF3) flanked by short 5’ and 3’
untranslated regions (UTRs) [224,225] (Fig. 12). The ORF1 encodes a large non-structural
protein with several putative functional motifs and domains such as methyltransferase,
papain-like cysteine protease (PCP), RNA helicase and RNA dependent RNA polymerase
(RdRp) [226]. The ORF2 encodes HEV capsid protein of 660 amino acids and encapsidate the
viral RNA genome [227]. The ORF3 of HEV encodes a small protein of 123 amino acids that is
essential for viral infectivity in vivo. Both the ORF2 and ORF3 proteins are translated from a
single bicistronic subgenomic RNA [228].
6.3. HEV genotypes and geographic distribution
Four major genotypes (genotypes 1-4) of mammalian HEV have been identified on the basis
of complete genome sequences [229,230]. Recently, partial sequence of HEV conserved region
(i.e. ORF1 and ORF2) reflects nucleotide sequence heterogeneity and hence genotyping of HEV
is possible without determining the entire genomic sequence [231,232] (Fig. 13). Regions within
nucleotides 171–221, 280–310 and 6461–6495 were most conserved and represented the best
targets for primer or probe design for genotyping and quantitation [232].
Figure 12. Genomic organization of HEV. HEV RNA is capped at the 5′ untranslated region (UTR) and polyadenylated
at the 3′ UTR. ORF1 encodes the nonstructural polyprotein; methyltransferase (MeT), papain-like cysteine protease
(PCP), RNA helicase (Hel) and RNA dependent RNA polymerase (RdRp). ORF2 encodes the viral capsid protein. ORF3
encodes a small regulatory phosphoprotein.(Adapted from: Ref. 222, 223 & 224)
Genotype 1 is mostly prevalent in Asia and Africa [230,233,234]. Genotype 2 is found in Central
and South America as well in African countries (Fig. 14). Both genotype 1 and 2 outbreaks are
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the result of efficient human-to-human feco-oral transmission mostly in developing countries
[231,234]. In industrialized countries, HEV genotype 1 infection is rare, therefore its presence
there is treated as imported infectious disease [231]. Genotype 3 includes human and swine
HEV strains from industrialized countries [235,236]. Finally, genotype 4 includes human and
swine HEV strains from Asia, particularly China, Taiwan and Japan [234,237]. HEV strains of
genotype 3 and 4 are maintained among animal species and occasionally infect humans
probably due to inefficient cross-species transmission [235].
Figure 13. Genotyping region of HEV. The most widely used HEV genomic regions for genotyping are indicated by
dotted line (…).
6.4. Genotype variations and disease severity
The severity of HEV associated acute hepatitis not only depends on the status of the host’s
immune system but also on viral factors such as genotypes. Hepatitis outbreaks in developing
countries have been caused primarily by HEV genotype 1. Most of the patients suffering from
hepatitis E caused by genotypes 1 are older children and young adults with mortality rate
1%[231,238]. A study from India reported that the viral load of genotype 1was significantly
higher in pregnant patients than in non-pregnant patients, and high viral load might be a
reason for severe liver disease in pregnant patients [239]. Genotype 2 is Mexican origin and
mostly prevalent in central American and African countries, like genotype 1, it is mostly self-
limiting. HEV genotype 3 is prevalent in industrialized nations and is rarely pathogenic.
Recently, it has been reported that genotype 4 infected patients showed more severe form of
the viral hepatitis than genotype 3 [240,241].
Most of the patients in this group belong to older age (~60 years) and the mortality rate is
relatively high (6-10%) [231,242]. Japanese study suggested that the silent substitutions of
U3148 and C5907 in the genotype 3 and 4 HEV strains are closely associated with the occur‐
rence of fulminant and severe cases and found that C5907 is associated with high HEV load
[243]. Thus, the genetic changes in hepatitis E virus genome may affect the effectiveness of
virus transmission and hence the severity of HEV-associated hepatitis. Therefore, examina‐
tion of HEV genotype is considered necessary in order to predict the clinical course and the
outcome.
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Figure 14. Worldwide geographic distribution of HEV: (Adapted from: Ref. 230,231,233,234 & 236)
6.5. HEV genotype and antiviral treatment response
Since most of the cases are self-limiting, acute HEV does not require antiviral therapy in
immunocompetent patients related to any genotype. The immunosuppressed patients should
be recommended ribavirin, so that these patients should not progressed to cirrhosis. Liver
transplantation is the only treatment option for patients with fulminant hepatic failure due to
HEV. All the four mammalian HEV strains belong to one serotype. Thus, only one hepatitis E
vaccine is needed for broad protection. The first phase of the immunoprophylaxis of HEV is
already tested for safety and immunogenicity [244]. The next phase is to make it available in
the market, especially in developing countries so that it should be effectively controlled.
7. Conclusions
The analysis of genomic sequence heterogeneity among different isolates of hepatitis viruses
(A-E) may provide an opportunity to decipher the course and pathogenesis of the virus.
Although, lot of information are available in this area but still there are many contradictions
and discrepancies.
HAV: There are contradictory findings regarding the role of nucleotide substitutions and
genotypic variations in disease severity among patients contracted with hepatitis A in different
geographical location.
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HBV: There are conflicting report about the role of HBV genotypes and severity of the disease
based on geographical distribution. Based on multiple studies, compared to genotype A and
B patients, C and D patients have a higher risk of disease progression (i.e. cirrhosis & HCC).
Similarly, genotype A and B patients responded better to interferon therapy than C and D
patients. It is important to note that few studies find no association between genotypes, disease
severity and response to treatment regimen.
HCV: Patients infected with any of the 6 HCV genotype can develop advanced liver disease,
including cirrhosis and HCC. However, some genotypes appear to be more severe compared
to the other. For example, genotype 1b is reported to be associated with a more severe and a
more aggressive course compared to genotype 2. Presently, it is recommended all the patients
irrespective of genotype should be given treatment, however treatment length depends on the
virus genotype.
HDV: There are contradictory outcomes about the role of HDV genotypes and disease severity.
At one geographical location HDV genotype 1 is associated with fulminant hepatitis and HCC
while at another location it is not severe. Other genotypes of HDV also have variable disease
severity based on geographical location.
HEV: Although HEV is self-limiting illness still it causes severe illness in pregnant women
with high mortality rate. Most of the pregnant women with aggressive course of the disease
are associated with genotype 1. There are lack of information regarding severity in pregnant
women and other genotypes. There are contradictory report regarding the severity of disease
and genotype 3 and 4, although a report from Japan suggests, silent substitutions of U3148 and
C5907 in the genotype 3 and 4 with response to fulminant hepatitis.
Therefore, the genomic heterogeneity of hepatitis viruses is not the only critical factor that
leads to disease progression, severity and final outcome. Hence, in combination with viral
genomic heterogeneity other factors such as age, sex, geographical distribution, genetic
polymorphism and host immune elements may play a vital role in deciding the clinical
implications and final outcome of the infection.
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